# Sensitivity Analysis of detriment calculation

Introducing Publication 152

Webinar December 9, 2022

Wei Zhang



#### **Detriment Calculation in Pub 103**

#### D = R (k + q (1-k)) I

Where: R is the lifetime risk k is the lethality fraction q is the adjusted lethality  $q=q_{min} + k(1-q_{min})$ l is the relative life lost



Risk of expose-induced cancer incidence: lifetime risk of cancer 'c' that has been caused by exposure 'D' at age 'e'.

$$REID_{\mathcal{C}}(e,D) = \int_{a=e+L}^{\infty} \left[ \mu_{\mathcal{C}}(a \mid e, D) - \mu_{\mathcal{C}}(a) \right] S(a \mid e, D) da$$

$$= \sum_{a=e+L}^{\infty} \left[ \mu_{c}(a \mid e, D) - \mu_{c}(a) \right] S(a \mid e, D)$$



## Variables involved in the lifetime risk calculation

- µ<sub>c</sub>(a) : cancer incidence rate
   at age 'a'
- µ<sub>c</sub>(a|e,D): cancer incidence rate which is conditional on exposure to dose 'D' at age 'e'
- S(a|e, D) : the survival function gives the probability of surviving to age 'a', given a dose 'D' at age 'e'.



## Detriment calculation for whole population in ICRP Publication 103

For each combination of geographical region (Asian and Euro-American), Sex (male and female)

- Lifetime risk was calculated at a single exposure of 0.1 Gy, then multiplied by 10.
- 5 years of latency were assumed as latency period for all cancers.
- For each age-at-exposure 0-89, lifetime risk was cumulated up to attained age of 94, then averaged over age-at-exposure.
- The averaged lifetime risk was averaged across models, with ERR:EAR of 0:100% for breast, 100:0% for thyroid, 30:70% for lung, and 50:50% for all other cancer sites.
- Lifetime risk was adjusted downward by a DDREF of 2, except for leukaemia.
- Adjustment for lethality, quality of life, relative life lost.



## How much does detriment vary if the Calculation parameters change?

- 1. Average over different age-at-exposure group (0-14, 18-64, 0-89yrs)
- 2. Male and female separately.
- 3. Euro-America, Asia population separately
- 4. 100%ERR and 100%EAR model separately
- 5. Different attained age (94 or 99 years)
- 6. Different latency period (5 or 10 years for solid cancer, 2 or 5 years for leukaemia.
- 7. Different DDREF
- 8. REIC versus LAR
- 9. Different exposure level (0.1 Gy versus 1 Gy)
- 10. Different lethality
- 11. Different minimum quality of life value
- 12. Different relative cancer-free life lost



#### Effect of age-at-exposure group





#### Sex effect





#### **Population effect**





#### **Modelling effect**



![](_page_9_Picture_2.jpeg)

#### Effect of attained age

![](_page_10_Figure_1.jpeg)

![](_page_10_Picture_2.jpeg)

## Latency effect

![](_page_11_Figure_1.jpeg)

![](_page_11_Picture_2.jpeg)

#### **Effect of DDREF**

![](_page_12_Figure_1.jpeg)

![](_page_12_Picture_2.jpeg)

### Sensitivity analysis

- Detriment increased by a factor of 2, with a DDREF of 1.
- For breast and ovary cancers, detriment increased by 2 if calculated for female only.
- For lung cancer, detriment for females appears to be higher than that for male, but the inverse is observed for liver, colon, and other solid cancers.
- For most cancer types, the detriment for the young age-at-exposure population (0-14) is higher than that of a whole population (0-89). For breast cancer, thyroid cancer and other solid cancer, the detriment for age-at-exposure 0-14 years is about 2-3 times higher compared with that of 0-89 years.

![](_page_13_Picture_5.jpeg)

#### **REIC and LAR**

$$REIC_c(e,D) = \int_{a=e+L}^{\infty} [\mu_c(a|e,D) - \mu_c(a)] S(a|e,D) da$$

$$LAR_{c}(e,D) = \int_{a=e+L}^{\infty} \left[\mu_{c}(a|e,D) - \mu_{c}(a)\right] S(a)da$$

![](_page_14_Picture_3.jpeg)

## S(a) versus S(ale,D) at 0.1 Gy

![](_page_15_Figure_1.jpeg)

![](_page_15_Picture_2.jpeg)

#### **Difference between REIC and LAR**

![](_page_16_Figure_1.jpeg)

![](_page_16_Picture_2.jpeg)

#### **Calculations at different exposure levels**

![](_page_17_Figure_1.jpeg)

![](_page_17_Picture_2.jpeg)

#### Lethality effect

![](_page_18_Figure_1.jpeg)

![](_page_18_Picture_2.jpeg)

### Effect of minimum quality of life

![](_page_19_Figure_1.jpeg)

![](_page_19_Picture_2.jpeg)

#### Effect of relative cancer-free life lost

![](_page_20_Figure_1.jpeg)

![](_page_20_Picture_2.jpeg)

### Sensitivity analysis

- There is very little difference between REIC and LAR if calculations are done at 0.1 Gy, and linearly extrapolate to risk at 1 Gy.
- In comparison to above mentioned method, REIC calculated at 1 Gy decreases for solid cancers, but increases for leukaemia by a factor of > 2, due to the effect of linear-quadratic dose response.
- For breast cancer and other solid cancers, detriment increases as lethality k increases.
- For lung and stomach cancers, the detriment increases as relative life lost increases.

![](_page_21_Picture_5.jpeg)

## Severity of impact

- Minimal impact (\*): a factor of change of < 1.5</li>
- Moderate impact (\*\*): a factor change of ≥ 1.5, and < 2</li>
- Substantial impact (\*\*\*): a factor change of ≥ 2

![](_page_22_Picture_4.jpeg)

## Impact of parameters

<ul> <li>Reference population</li> </ul>	Impact severity
sex	***
population	**
age-at-exposure	***
<ul> <li>Parameter for risk calculation</li> </ul>	
lifetime risk metric:	*
Dose (0.1 Gy Vs. 1 Gy):	***
latency:	*
Maximum attained age:	*
Model transfer:	**
DDREF:	***
<ul> <li>Severity adjustment</li> </ul>	
Lethality fraction:	***
Min. QOL factor:	*
Relative cancer-free life lost:	**

![](_page_23_Picture_2.jpeg)

## Summary of sensitivity analysis

- Slight variation of detriment to latency, attained age, lifetime risk calculation method (calculated at low dose) or min. quality of life
- Noticeable variation of detriment with population, transfer model (100%ERR or 100%EAR Model) and relative life lost.
- Sex has a major impact for certain cancer types. Need to think about whether lifetime risk for breast cancer and ovary cancer should be averaged over sex.
- The age-at-exposure has a major impact on detriment, with much smaller detriment for 0-89 years group than 0-14 years group for some cancer types.
- DDREF and lethality also have major impact on cancer detriment.

![](_page_24_Picture_6.jpeg)

### www.icrp.org

![](_page_25_Picture_1.jpeg)